1. Home » 
  2. Markets » 
  3. Sakar Healthcare Signs Confidential Agreements with Three Indian Multinationals

Sakar Healthcare Signs Confidential Agreements with Three Indian Multinationals

Sakar Healthcare secures agreements with Dr. Reddy's Laboratories, Biocon Pharma, and Emcure Pharmaceuticals for confidential oncology API and FDF development.  

by Damodharan N

Updated Jul 18, 2024

Article continues below advertisement
Sakar Healthcare Signs Confidential Agreements with Three Indian Multinationals

Sakar Healthcare has announced the signing of confidential agreements with prominent Indian pharmaceutical companies, including Dr. Reddy's Laboratories, Biocon Pharma, and Emcure Pharmaceuticals.

These agreements focus on the development of API intermediates and finished dosage formulations (FDF) in the oncology sector. Sakar's EU GMP approved manufacturing unit will play a crucial role in the scale-up and production of oral solids and injections, aimed at enhancing the robustness of manufacturing processes and facilitating technology transfer for specialized FDFs.

Sakar will also align its technology-transfer processes to cater to niche finished dosage forms, while organizing its skill sets to deliver comprehensive solutions within the cytotoxic This strategic move is expected to strengthen Sakar's position as a trusted partner in oncology solutions for multinational pharmaceutical firms.

Get the announcement here

Sakar Healthcare 

Established in 2004, Sakar Healthcare specializes in manufacturing pharmaceutical products including liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections.

Operating as a Contract Development and Manufacturing Organization (CDMO), Sakar is EU GMP approved and serves leading multinational pharmaceutical companies. With state-of-the-art facilities certified by ISO 9001:2015, WHO-GMP, and other international standards.

 Sakar exports to over 50 countries across Africa, SEASIA, CIS, Latin & Central America, and Europe. The company is known for its commitment to quality and innovation in the global pharmaceutical industry, recently expanding its capabilities to include oncology finished dosage manufacturing with EU GMP approved units for both oral solids and injections.


Sakar Healthcare Signs Confidential Agreements with Three Indian Multinationals - FAQs

1. What is the focus of Sakar Healthcare's recent agreements?   

Development of oncology API intermediates and finished dosage formulations (FDF).

2. Which companies has Sakar Healthcare partnered with?   

Dr. Reddy's Laboratories, Biocon Pharma, and Emcure Pharmaceuticals.

3. What role does Sakar Healthcare's manufacturing unit play?   

Scaling up and producing oral solids and injections for oncology products.

4. How does Sakar aim to enhance its manufacturing processes?   

By strengthening robustness and facilitating technology transfer for specialized FDF.

5. What are the expected outcomes of these agreements?   

Facilitate technology transfer and enhance capabilities in niche oncology products.

6. What geographical regions does Sakar Healthcare serve?   

Over 50 countries across Africa, SEASIA, CIS, Latin & Central America, and Europe.

7. What certifications does Sakar Healthcare hold?   

Sakar Healthcare holds ISO 9001:2015, WHO-GMP, and other international standards.

8. How does Sakar Healthcare describe its business model?   

Contract Development and Manufacturing Organization (CDMO) for multinational companies.

9. What are Sakar Healthcare's core product categories?   

Liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections.

Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.